Journal article
Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
Gastroenterology (New York, N.Y. 1943), Vol.167(5), pp.1008-1018.e5
10/2024
DOI: 10.1053/j.gastro.2024.06.028
PMID: 38964420
Abstract
Homozygous ZZ alpha-1 antitrypsin (AAT) deficiency produces mutant AAT (Z-AAT) proteins in hepatocytes, leading to progressive liver fibrosis. We evaluated the safety and efficacy of an investigational RNA interference therapeutic, fazirsiran, that degrades Z-AAT mRNA, reducing deleterious protein synthesis.
This ongoing, phase 2 study randomized 40 patients to subcutaneous placebo or fazirsiran 25/100/200 mg. The primary endpoint was percentage change in serum Z-AAT concentration from baseline to Week 16. Patients with fibrosis on baseline liver biopsy received treatment on Day 1, Week 4, and then every 12 weeks, and had a second liver biopsy at or after Weeks 48, 72, or 96. Patients without fibrosis received two doses on Day 1 and Week 4.
At Week 16, least-squares mean percent declines in serum Z-AAT concentration were −61%, −83% and −94% with fazirsiran 25/100/200 mg, respectively, versus placebo (all P< .0001). Efficacy was sustained through Week 52. At post-dose liver biopsy, fazirsiran reduced median liver Z-AAT concentration by 93% compared with an increase of 26% with placebo. All fazirsiran-treated patients had histological reduction from baseline in hepatic globule burden. Portal inflammation improved in 5/12 and 0/8 patients with baseline score >0 in the fazirsiran and placebo groups, respectively. Histological METAVIR score improved by >1 point in 7/14 and 3/8 patients with fibrosis >F0 at baseline in the fazirsiran and placebo groups, respectively. No adverse events led to discontinuation and pulmonary function tests remained stable.
Fazirsiran reduced serum and liver concentrations of Z-AAT in a dose dependent manner and reduced hepatic globule burden (NCT03945292).
[Display omitted]
Details
- Title: Subtitle
- Fazirsiran for Adults with Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
- Creators
- Virginia C. Clark - University of FloridaCharlie Strange - Medical University of South CarolinaPavel Strnad - Department of Internal Medicine III, University Hospital, RWTH (Rheinisch–Westfälische Technische Hochschule) Aachen University, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, GermanyAntonio J. Sanchez - University of IowaPaul Kwo - Stanford UniversityVitor Magno PereiraBart van Hoek - Leiden University Medical CenterIgor Barjaktarevic - University of California, Los AngelesAngelo Guido Corsico - University of PaviaMonica Pons - Hebron UniversityMonica Goldklang - Columbia University Irving Medical CenterMeagan Gray - University of FloridaBrooks KuhnHugo E. Vargas - Mayo Clinic in ArizonaJohn M. Vierling - Baylor College of MedicineRaj Vuppalanchi - Indiana University School of MedicineMark Brantly - University of FloridaNaomi Kappe - Leiden University Medical CenterTing Chang - Arrowhead Pharmaceuticals (United States)Thomas Schluep - Arrowhead Pharmaceuticals (United States)Rong Zhou - Arrowhead Pharmaceuticals (United States)James Hamilton - University of FloridaJavier San Martin - Arrowhead Pharmaceuticals (United States)Rohit Loomba - University of California San Diego
- Resource Type
- Journal article
- Publication Details
- Gastroenterology (New York, N.Y. 1943), Vol.167(5), pp.1008-1018.e5
- DOI
- 10.1053/j.gastro.2024.06.028
- PMID
- 38964420
- NLM abbreviation
- Gastroenterology
- ISSN
- 0016-5085
- eISSN
- 1528-0012
- Publisher
- Elsevier Inc
- Language
- English
- Electronic publication date
- 07/02/2024
- Date published
- 10/2024
- Academic Unit
- Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9984656556402771
Metrics
19 Record Views